Fig. 7: Combination of MCL-1 inhibition and CD19 CAR-T therapy overcomes resistance in aggressive B-cell lymphoma. | Leukemia

Fig. 7: Combination of MCL-1 inhibition and CD19 CAR-T therapy overcomes resistance in aggressive B-cell lymphoma.

From: Synthetic lethality of MCL-1 inhibition and CAR-T therapy in aggressive B-cell lymphoma

Fig. 7

A Cell cytotoxicity assay showing CD19 CAR-T cell-mediated killing in paired S63845-sensitive parental and S63845-resistant lymphoma cell lines. B Cell viability assay assessing the dose response of S63845 in paired CD19 CAR-T sensitive and resistant lymphoma cells. C Cell cytotoxicity assay shows the response of combination of S63845 and CD19 CAR-T in CD19 CAR-T resistant cells (CD19-R). D Survival analysis of mice treated with indicated therapies; statistical analysis was determined using the Mantel-Cox test. n = 6 for each group.

Back to article page